Coxibs - Past Problems and Future Potential

Questions: Discounts, Updates etc.

Pages: 62

Price (Single): £550

Price (Departmental): £950

Price (Company): £1950

Publication Date: 2006-10-01

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Spanning the field of pain, inflammation and oncology, as well as more recently for unwanted reasons, cardiovascular disease the cyclooxygenase-2 (COX-2 or Coxibs) have sat in the spot light for almost a decade now.

The first Coxib, Celebrex (celecoxib), arrived on the market in 1998 rapidly becoming a blockbuster soon to be followed by another equally successful drug from the same class, Vioxx (rofecoxib).  Soon after however, cardiovascular adverse effects were found to be associated with Vioxx leading to its withdrawal and sparking the start of a turbulent period affecting not only Vioxx, but the Coxib class as a whole and more generally all NSAIDs.

LeadDiscovery’s report Coxibs - Past Problems…Future Potential was written to provide all in the drug development sector a detailed look at the events leading up to the withdrawal of Vioxx, the status of the Coxib class  2 years on and its future potential. 

Far from slipping into the pharmaceutical backwater this class continues to provide blockbuster revenues for Pfizer and potential for others.  This report is key to companies considering reentry into the COX-2 arena and those developing other analgesics that could canabilize the coxib market.  The report is also written with the aim of guiding companies investing in chemoprevention and Alzheimer’s disease, indications that have been investigated as target for the Coxibs.

Against a backdrop of litigations brought against Merck & Co and new regulatory guidelines for the coxibs, Pfizer’s Celebrex generated $1.7 billion in revenue last year and continues to win approval for new indications, the most recent being ankylosing spondylitis.  The continued potential of the Coxibs is evidenced by clear activity of this class in the prevention of certain pre-cancerous growths and uncertainty over the cardiovascular safety of NSAIDs.  Most recently data has emerged offering a possible explanation behind the cardiovascular activity of the Coxibs offering the potential to rationally design new agents with improved therapeutic margins.

Coxibs - Past Problems...Future Potential is designed to help readers address questions such as:

Table of Contents

The biology of the cyclooxygenase pathway

An introduction to COX inhibitors

The rational for Coxib development

Clinical data on approved and late stage Coxibs

Differentiating the risk of COX-2 inhibitor family members

Clinical data supporting use of Coxibs for new indications

Safety recommendations following reintroduction of COX-2

Regulatory stand point

Current status of approved Coxibs, future events & pipeline agents

Knock-on effect of Vioxx's withdrawal

Emerging alternatives to COX-2 inhibitors

Conclusions & Recommendation on future use of Coxibs

Other users found this report page using the following search terms: cox cox-2 coxib celebrex vioxx coxibs coxib future sales effects use market vioxx cox2 generation

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.